Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endurance3: Long-Term Aflibercept for DME
NCT02734407Phase 4Completed
- Sponsor
- Retina-Vitreous Associates Medical Group
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Retina-Vitreous Associates Medical Group. Primary endpoints: Mean number of intravitreal aflibercept injections in 52 weeks, Proportion of subjects receiving 0 aflibercept injections in 52 weeks and 2 more. Started Jan 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02734407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734407.